Promising New Treatment Shows Early Success for Prader-Willi Syndrome

Rhythm Pharmaceuticals (RYTM) announces positive results from Phase 2 trial of setmelanotide for Prader-Willi syndrome, showing BMI reduction and decreased hunger in patients.